It’s not necessarily a funding issue, the response rates in the phase 2 were just underwhelming. It still helped a subset but the group effect just wasn’t enough. There is however a problem with the way stuttering is measured in clinical trials as placebo response is usually strong. An example of this being as the participants become more comfortable every time they go back for the next assessment, their speech naturally improves as they have less anxiety (anxiety makes stuttering worse). So because the placebo group usually improves, the medication has to perform very well to clearly beat placebo, and without a large group effect this is obviously difficult. A new measuring/rating system was produced this year and it’s tailored based on what the feedback was from the fda on past rating systems in previous trials. Big steps are being made but unfortunately I believe it’ll be some time yet before we have anything on the market. However there are off label medications that can improve stuttering for many people now, it’s just the side effects can be very harsh particularly long term (metabolic issues, movement disorders etc.) Hope this helps! See my original reply for more detail https://www.reddit.com/r/Stutter/s/hvGd8jCo55